CoChat

Low Mpl receptor expression in a pedigree with familial platelet disorder with predisposition to acute myelogenous leukemia and a novel AML1 mutation.

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

Germ-line heterozygous mutations in the hematopoietic transcription factor AML1 (RUNX1) have been identified in patients with familial platelet disorder with predisposition to acute myelogenous leukemia (FPD/AML), which is characterized by thrombocytopenia, abnormal platelet function, and propensity to myeloid malignancies. We identified a novel mutation in the AML1 gene in an FPD/AML pedigree characterized by a single nucleotide deletion that generates a frameshift and premature chain termination (Pro218fs-Ter225). Both wild-type and mutant transcripts were expressed in affected individuals by allele-specific reverse transcriptase-polymerase chain reaction (RT-PCR). Thrombopoietin (TPO) binds to the Mpl receptor and is the major regulator of megakaryopoiesis. To explore the mechanisms underlying thrombocytopenia, we studied the TPO/Mpl pathway in this newly identified pedigree. TPO levels were mildly to moderately elevated. On flow cytometry and immunoblotting, Mpl receptor expression was decreased and TPO-induced signaling was impaired. While no mutations were identified in the MPL gene by sequence analysis, low MPL mRNA levels were found, suggesting decreased gene expression. Of particular interest, several AML1-binding motifs are present in the MPL promoter, suggesting MPL is an AML1 target. In conclusion, we identified a C-terminal AML1 mutation that leads to a decrease in Mpl receptor expression, providing a potential explanation for thrombocytopenia in this FPD/AML pedigree.

Overview

Integrity signals

Registry

Crossref · 10.1182/blood-2005-01-0050

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 35 references

Cited by

See all 107

Metadata

Authors
Heller, P. G., Glembotsky, A. C., Gandhi, M. J., Cummings, C. L., Pirola, C. J., Marta, R. F., Kornblihtt, L. I., Drachman, J. G., & Molinas, F. C.
Affiliations
University of Washington (US)
Venue
Blood
Published
2005-06-15
Volume
105
Issue
12
Pages
4664-4670
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2058237334
Cited by
104
References
35
Citations by year
2025: 3 · 2024: 4 · 2022: 2 · 2020: 5 · 2019: 8 · 2018: 3 · 2017: 9 · 2016: 7 · 2015: 6 · 2014: 6 · 2013: 4 · 2012: 7
FWCI
4.53
Type
journal article
Language
en
Open access
closed
Locations
  • Blood (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Health Sciences › Medicine › Hematology › Blood disorders and treatments
Keywords
RUNX1, Mpl receptor, thrombopoietin signaling, thrombocytopenia, frameshift mutation, megakaryopoiesis, C-terminal mutations
MeSH terms
Adolescent, Adult, Alleles, Blood Platelet Disorders, Blood Platelets, DNA, DNA-Binding Proteins, Electrophoresis, Polyacrylamide Gel, Exons, Family Health, Female, Flow Cytometry, Gene Expression Regulation, Heterozygote, Humans, Male, Middle Aged, Models, Genetic, Mutation, Pedigree, Phosphorylation, Promoter Regions, Genetic, Protein Binding, Proto-Oncogene Proteins, RNA, Messenger, Thrombocytopenia, Thrombopoietin, Transcription Factors, Tyrosine, Immunoblotting, Blotting, Western, Signal Transduction, Leukemia, Myeloid, Acute, Frameshift Mutation, DNA Primers, Germ-Line Mutation, Receptors, Cytokine, Genetic Predisposition to Disease, Reverse Transcriptase Polymerase Chain Reaction, Amino Acid Motifs, Core Binding Factor Alpha 2 Subunit, Receptors, Thrombopoietin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Low Mpl receptor expression in a pedigree with familial platelet disorder with predisposition to acute myelogenous leukemia and a novel AML1 mutation. https://app.cochat.ai/papers/10.1182/blood-2005-01-0050
The paper
Heller, P. G., Glembotsky, A. C., Gandhi, M. J., Cummings, C. L., Pirola, C. J., Marta, R. F., Kornblihtt, L. I., Drachman, J. G., & Molinas, F. C. (2005). Low Mpl receptor expression in a pedigree with familial platelet disorder with predisposition to acute myelogenous leukemia and a novel AML1 mutation. Blood. https://doi.org/10.1182/blood-2005-01-0050

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.